Evaluation of Periodontal Status and Cytokine Response in Inflammatory Bowel Diseases
Objectives: Inflammatory bowel diseases (IBD) and chronic inflammatory periodontal diseases are characterized by host immunoinflammatory response and multifactorial etiology. In patients with IBD, as well as intestinal findings, lesions associated with oral cavity may also be seen. The aim of the study is; to evaluate the periodontal status in children with IBD and to determine the local (GCF) and systemic (serum) cytokine responses.
Methods: In this study 28 patients with IBD (case group) and 21 systemically healthy children (control group) were included. Disease activity levels of patients with IBD were defined by disease activity indices based on clinical and laboratory findings. Complete blood count, serum alkaline phosphatase (ALP), C-reactive protein (CRP), vitamin D, calcium (Ca) and phosphate (P) levels of routine laboratory tests of these patients were recorded. On clinical examinations, gingival index (GI), plaque index (PI), bleeding on probing (BoP), probing depth (PD) and clinical attachment level (CAL) were measured. Also, blood and GCF samples were collected to determine cytokine levels (IL-1β, IL-4, IL-10, IL-12, IL-21, IL-22, IL-23, IL-17A, IL-17F). ELISA protocols are still being worked to detect cytokines in blood and GCF.
Results: The present study was performed with 28 patients (8 female, 20 male; aged 12,2±4,3) and 21 control subjects (9 female, 12 male; aged 10,7±2,7). There were no significant differences in terms of age, sex and plaque levels between the groups. Although, GCF volume was higher in the case group, there were no significant differences in GI and BoP. Significant positive correlations were found between GI, serum total protein and monocyte levels. Moreover, BoP was significantly correlated with neutrophil value.
Conclusions: Periodontium can be influenced by IBD, which is not limited to the intestine, also causes systemic chronic inflammation. ELISA results will enlighten about the relation between local (GCF) and systemic (serum) immunoinflammatory responses in IBD patients.